Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients

Neuropsychopharmacology

Volumn 14, Issue 4, 1996, Pages 275-283

  Van Kammen, Daniel P ^a,b,c   Kelley, Mary E ^a   Gurklis, John A ^b   Gilbertson, Mark W ^b   Yao, Jeffrey K ^a,b   Condray, Ruth ^a,b   Peters, Jeffrey L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CSF; Dopamine; Norepinephrine; Relapse prediction; Schizophrenia; Serotonin

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; HALOPERIDOL; HOMOVANILLIC ACID; SEROTONIN;

ADULT; ANXIETY; ARTICLE; BEHAVIOR; CEREBROSPINAL FLUID; DRUG RESISTANCE; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; RISK FACTOR; SCHIZOPHRENIA;

EID: 0029874893     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00135-Z     Document Type: Article

References (73)

1. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, rev ed 3. Washington, DC, American Psychiatric Association
2. Andrews P, Hall JN, Snaith RP (1976): A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. Br J Psychiatr 128:451-455
3. Angrist B, Burrows GD, Lader M, Lingjaerde O, Sedvall G, Wheatly D (1981): Relationships between responses to dopamine agonists: Psychopathology, neuroleptic treatment response, and need for neuroleptic maintenance in schizophrenic subjects. In Angrist B, Peselow E, Rotrosen J, Gershon S (eds), Recent Advances in Neuropsychopharmacology. Oxford, Pergamon, pp 49-54
4. 2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm 85:19-29
5. Åsberg M, Bertilsson L, Rydin E, Schalling D, Thoren P, Traskman-Bendz L (1981): Monoamine metabolites in cerebrospinal fluid in relation to depressive illness, suicidal behavior and personality. In Angrist B, Burrows GD, Lader M (eds), Recent Advances in Neuropsychopharmacology. Oxford, Pergamon, pp 257-271
6. Beuger M, van Kammen DP, Kelley ME, Yao JK (in press): Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma and urine studies. Neuropsychopharmacol
7. Bleuler M (1978): The Schizophrenic Disorders: Long-Term Patient and Family Studies. New Haven, Yale University Press
8. Brown GL, Goodwin FK, Ballenger JC, Goyer PF (1981): Cerebrospinal fluid amine metabolites and cyclic nucleotides in human aggression. Psychopharmacol Bull 17:63-65
9. Buchanan A (1992): A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 22:787-797
10. Buchanan RW Kirkpatrick B, Summerfelt A, Hanlon TE, Levine J, Carpenter WT (1992): Clinical predictors of relapse following neuroleptic withdrawal. Biol Psychiatr 32:72-78
11. Bunney WE Jr, Hamburg DA (1963): Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatr 9:280-294
12. Cannon-Spoor HE, Potkin SG, Wyatt RJ (1982): Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 8:460-484
13. Carpenter WT, Hanlon TE, Heinrichs DW, Summerfelt AT (1990): Continuous versus targeted medication in schizophrenic outpatients: Outcome results. Am J Psychiatr 147:1138-1148
14. Cheng HC, Long JP (1973): Effects of d-and 1-amphetamine on 5-hydroxytryptamine receptors. Arch Int Pharmacodyn 204:124-131
15. Cohen BM, Benes FM, Baldessarini RJ (1989): Atypical neuroleptics, dose relationships, and treatment resistant psychosis. Arch Gen Psychiatr 46:381-383
16. Cox DR (1972): Regression model and life tables. J Royal Stat Soc (Series B) 34:187-220
17. Davidson M, Keefe RSE, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL (1987): L-dopa challenge and relapse in schizophrenia. Am J Psychiatr 144:934-938
18. Davis JM (1975): Overview: Maintenance therapy in psychiatry: Schizophrenia. Am J Psychiatr 132:1237-1245
19. Dencker SJ, Malm U, Lepp M (1986): Schizophrenic relapse after drug withdrawal is predictable. Acta Psychiatr Scand 73:181-185
20. Docherty JP, van Kammen DP, Siris SG, Marder SR (1978): Stages of onset of schizophrenia psychosis. Am J Psychiatr 135:420-426
21. Falloon IRH, Marshall GN, Boyd JL, Razani J, Wood-Siverio C (1983): Relapse in schizophrenia: A review of the concept and its definitions (Editorial). Psychol Med 13:469-477
22. Gaebel W, Frick U, Köpcke W, Linden M, Müller P, Müller-Spahn F, Pietzcker A, Tegeler J (1983): Early neuroleptic intervention in schizophrenia: Are prodromal symptoms valid predictors of relapse? Br J Psychiatr 163:S8-S12
23. Graham AW, Aghajanian GK (1971): Effects of amphetamine on single cell activity in a catecholamine nucleus, the locus coeruleus. Nature 234:100-102
24. Greenhouse JB, Kupfer DJ, Frank E, Jarrett DB, Rejman KA (1987): Analysis of time to stabilization in the treatment of depression: Biological and clinical correlates. J Affect Dis 13:259-266
25. Groves P, Ryan L, Diana M, Gariano R (1988): Neurophysiological consequences of amphetamine administration. NIDA Res Mon 90:213-222
26. Herz MI, Glazer WM, Mostert A, Sheard MA, Szymanski HV, Hafez H, Mirza M, Vana J (1991): Intermittent vs. maintenance medication in schizophrenia. Arch Gen Psychiatr 48:333-339
27. Hirsch SR, Jolley AG, Morrison E, McRink A, Wilson L (1990): Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical and social outcome at 2 years. Schizophr Res 3:40
28. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF (1974): Drug and psychotherapy in the aftercare of schizophrenic patients: II. Two year relapse rates. Arch Gen Psychiatr 31:603-608
29. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Ulrich RF, Carter M, EPICS research group (1991): Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. Arch Gen Psychiatr 48:340-347
30. Hsiao JK, Potter WZ, Agren H, Owen RR, Pickar D (1993): Clinical investigation of monoamine neurotransmitter interactions. Psychopharmacology 112:S76-S84
31. Johnson DAW, Pasterski G, Ludlow JM, Street K, Taylor RDW (1983): The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: Drug and social consequences. Acta Psychiatr Scand 67:339-352
32. Jolley AG, Hirsch SR, McRink A, Manchanda R (1989): Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical outcome at one year. Br Med J 298:985-990
33. Joyce JN (1993): The dopamine hypothesis of schizophrenia: Limbic interactions with serotonin and norepinephrine. Psychopharmacology 112:S16-S34
34. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE (1993): Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8:315-336
35. Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL (1993): Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatr 50:599-605
36. Kane JM (1987): Neuroleptic treatment of schizophrenia. In Henn FA, Delisi LE, (eds), Handbook of Schizophrenia: Neurochemistry and Neuropharmacology of Schizophrenia, New York, Elsevier, pp 179-201
37. Kane JM, Lieberman JA (1987): Maintenance pharmacotherapy in schizophrenia. In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress. New York, Raven, pp 1103-1109
38. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Scheibel D, Ramos-Lorenzi J (1983): Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatr 40:893-896
39. Kane JM, Rifkin A, Woerner M, Reardon G, Kreisman D, Blumenthal R, Borenstein M (1985): High-dose versus low-dose strategies in the treatment of schizophrenia. Psychopharmacology Bull 21:533-537
40. Kaplan EL, Meier P (1958): Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
41. Kissling W (ed) (1991): Guidelines for Neuroleptic Relapse Prevention. Berlin, Springer-Verlag
42. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE (1993): Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: A postmortem study. Arch Gen Psychiatr 50:810-818
43. Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J (1987): Prediction of relapse in schizophrenia. Arch Gen Psychiatr 44:597-603
44. Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, Cooper T, Kane JM (1994): Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 11:107-118
45. Lin PYT, Bulawa MC, Wong P, Lin L, Scott J, Blank CL (1984): The determination of catecholamines, indoleamines, metabolites, and related enzymatic activities: Using three micron liquid chromatography columns. J Liquid Chromatol 7:509-518
46. Linnoila M, Ninan PT, Scheinin M, Waters RN, Chang WH, Bartko J, van Kammen DP (1983): Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients. Arch Gen Psychiatr 40:1290-1294
47. Linnoila M, Dejong J, Virkkunen M (1989): Monoamines, glucose metabolism, and impulse control. Psychopharmacol Bull 25:404-406
48. Marder SR, van Kammen DP, Bunney Jr WE (1979): Prediction of drug-free improvement in schizophrenic psychosis. Arch Gen Psychiatr 36:1080-1085
49. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PRA (1987): Low-and conventional-dose maintenance therapy with fluphenazine decanoate: Two-year outcome. Arch Gen Psychiatr 44:518-521
50. Meltzer HY (1989): Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27
51. Meyer A (1922): Constructive formulation of schizophrenia. Am J Psychiatr 78:355-364
52. 2 receptors in chronic schizophrenics. Biol Psychiatr 21:1407-1414
53. Ninan PT, van Kammen DP, Scheinin M, Linnoila M, Bunney WE Jr, Goodwin FK (1984): CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. Am J Psychiatr 141:566-569
54. Nuechterlein KH, Dawson ME (1984): A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull 10:300-312
55. Scheinin M, Chang W-H, Kirk JL, Linnoila M (1983): Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol 5-hydroxyindolacetic acid, and homovanillic acid in CSF with high performance liquid chromatography using electrochemical detection. Anal Biochem 131:246-253
56. Schooler NR (1993): Reducing dosage in maintenance treatment of schizophrenia. Br J Psychiatr 163(Supp 22):58-65
57. Selvin S (1991): Statistical Analysis of Epidemiologic Data. Monographs in Epidemiology and Biostatistics, Vol 17. New York, Oxford University Press
58. Spitzer RL, Endicott J (1979): The Schedule for Affective Disorders and Schizophrenia - Lifetime version, ed 3. New York, New York State Psychiatric Institute, Biometrics Research
59. Strauss JS, Hafez H, Lieberman P, Harding CM (1985): The course of psychiatric disorder. III. Longitudinal principles. Am J Psychiatr 142:289-296
60. Szymanski HV, Simon JC, Gutterman N (1983): Recovery from schizophrenic psychosis. Am J Psychiatr 140:335-338
61. van Kammen DP (1991): The biochemical basis of relapse and drug response in schizophrenia: Review and hypothesis. Psychol Med 21:881-895
62. van Kammen DP, Antelman SM (1984): Impaired noradrenergic transmission in schizophrenia? Minireview. Life Sci 34:1403-1413
63. van Kammen DP, Kelley M (1991): Dopamine and norepinephrine activity in schizophrenia: An integrative perspective. Schizophr Res 4:173-191
64. van Kammen DP, Sternberg DE (1980): CSF studies in schizophrenia. In Wood JH (ed), Neurobiology of Cerebrospinal Fluid, Vol I. New York, Plenum, pp 719-742
65. van Kammen DP, Docherty JP, Bunney WE Jr (1982): Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biol Psychiatr 17:233-242
66. van Kammen DP, Peters JL, van Kammen WB, Nugent A, Goetz KL, Yao J, Linnoila M (1989): CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatr 26:176-181
67. van Kammen DP, Galanter J, van Kammen WB, Nealon P, Dougherty G, Peters J (1993): Respite care for chronic schizophrenic patients: Does it prevent crisis oriented admissions? In Hinterhuber H, Kulhanek F, Fleischhacker WW, Neumann R (eds), Prädiktoren und Therapieresistenz in der Psychiatrie. Braunschweig-Wiesbaden, Viewig, pp 97-109
68. van Kammen DP, Ågren H, Yao JK, O'Connor DT, Gurklis J, Peters JL (1994): Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am J Psychiatr 151:379-384
69. van Kammen DP, Kelley ME, Gurklis J, Gilbertson MW, Peters JL (1995): Behavioral vs. biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. Arch Gen Psychiatr 52:673-678
70. van Praag HM (1986): Affective disorders and aggression disorders: Evidence for a common biological mechanism. Suicide Life-Threatening Behav 16:21-132
71. Ventura J, Nuechterlein KH, Hardesty JP, Gitlin M (1992): Life events and schizophrenic relapse after withdrawal of medication. Br J Psychiatr 161:615-620
72. Weiden PJ, Dixon L, Frances A, Appelbaum P, Haas G, Rapkin B (1991): Neuroleptic noncompliance in schizophrenia. In Tamminga CA, Schulz SC (eds), Advances in Neuropsychiatry and Psychopharmacology, Vol. I. Schizophrenia Research. New York, Raven, pp 285-296
73. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon, Frances A (1994): Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 20: 297-310